Novo Nordisk reports significant weight loss with amycretin
The amylin and GLP-1 co-agonist is Novo's next obesity candidate behind semaglutide and CagriSema.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 2 11:30 ETSource: BusinessWorld Online
The wire
- 01BusinessWorld reports that Novo Nordisk's amycretin, a combined amylin and GLP-1 receptor agonist, produced significant weight loss in trial results disclosed by the company.
- 02Amylin analogs are the next mechanism after incretins, and clinicians following obesity pharmacotherapy will want to track how amycretin is positioned against CagriSema.
- 03Specific doses, endpoints and trial size were not detailed in the report; full data and regulatory timing remain unclear.
From the source
Read at bworldonline.comnovo nordisks new drug amycretin shows significant weight loss
